Want to see GB:TCF full AI Analyst Report?
TCF Stock Chart & Stats
0.20 p
0.00 p(0.00%)
At close: 4:00 PM EST
0.20 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.18 p - 0.30 p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.69M
Market Cap
£4.62M
Enterprise Value3.60M
Total Cash (Recent Filing)£3.50M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Dec 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,148,963,600
10 Day Avg. Volume2,190,584
30 Day Avg. Volume1,685,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA lack of reported debt materially reduces solvency and interest-cost risk, giving management flexibility to prioritize R&D and partnership negotiations over the next several months. This durable capital-structure strength lowers bankruptcy risk and improves options for non-dilutive financing or strategic deals.
Stabilized Lead Program (SFX-01) Targeting Nrf2Owning a stabilized sulforaphane formulation that targets the Nrf2 pathway represents a differentiated clinical asset and proprietary formulation. As a platform-focused clinical program, SFX-01 offers durable scientific rationale and potential for multiple indications, supporting longer-term partner interest and development optionality.
Partnering/licensing-centric Business ModelA business model built on licensing and partnering is structurally aligned with clinical-stage biotech economics: it can generate non-dilutive milestones and royalties, allowing Evgen to de-risk commercialization capital requirements. Over 2–6 months this reduces the need to build large in-house commercial capabilities.
Bears Say
Persistent Cash Burn And Negative Cash FlowConsistent negative operating and free cash flows force reliance on external funding (equity, grants, or deals). Even with improvement in 2025, ongoing cash burn is a durable constraint that can dilute shareholders, delay programs, or pressure management to accept suboptimal partnerships within a 2–6 month horizon.
Structurally Loss-making OperationsRepeated negative EBIT/EBITDA and net losses indicate the company lacks a profitable operating model at present. This persistent unprofitability erodes equity, limits retained-capital accumulation, and constrains strategic options without external capital or a material change in revenue trajectory over the medium term.
Small, Inconsistent Revenue BaseIrregular and minimal revenues make forecasting and investment planning difficult and increase dependency on milestone payments or grants. This structural revenue unpredictability reduces bargaining power with partners and heightens execution risk for sustaining multi-stage clinical programs over the next several months.
Evgen Pharma News
TCF FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest share price was 0.17 p and its highest was 0.30 p in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is £4.62M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Dec 09, 2026 which is in 160 days.
How were Evgen Pharma PLC’s earnings last quarter?
Currently, no data Available
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in GB:TCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evgen Pharma PLC
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma. The company's pipeline also includes an orexin 1 antagonist, which is in the late preclinical stage for addressing addiction and anxiety, alongside an atypical dopamine transporter inhibitor (DAT) at a similar development stage, targeting fatigue and narcolepsy. Incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, the company rebranded from Evgen Pharma plc to Theracryf Plc in April 2024.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Options Prices
Currently, No data available
---